ConductScience.org, home

Paper37814061

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.

Anagnostou V and 19 others. Nat Med, 2023. Cited by 152 papers, by iCite.

Cite this record

ConductScience Library. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Papers, record 37814061. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37814061

Download JSON
Disease
lung cancer261 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
PubMed
Journal
Nat Med
PubMed
Year
2023
PubMed
Publication types
Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Adaptive Clinical Trial
PubMed
Citations, by iCite
152
iCite
Relative citation ratio, by iCite
10.4
iCite
Revised in PubMed
2025-01-31
PubMed

Authors20

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Anagnostou VValsamohttps://orcid.org/0000-0001-9480-3047
2Ho CCheryl
3Nicholas GGarth
4Juergens RARosalyn Anne
5Sacher AAdrian
6Fung ASAndrea S
7Wheatley-Price PPaul
8Laurie SAScott A
9Levy BBenjamin
10Brahmer JRJulie R
11Balan AArchana
12Niknafs NNoushin
13Avrutin EEgor
14Zhu LLiting
15Sausen MMarkhttps://orcid.org/0000-0002-2916-5269
16Bradbury PAPenelope A
17O'Donnell-Tormey JJill
18Gaudreau POPierre Olivier
19Ding KKeyue
20Dancey JJanet

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Humans
Antibodies, Monoclonal, Humanized
Progression-Free Survival

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 CA121113NCI NIH HHSUnited StatesR01CA121113PubMed and NIH
CA121113NIH HHSUnited StatesR01CA121113PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT04093167Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung CancerDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128864724Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.Clin Cancer Res2017https://conductscience.org/library/papers/28864724PubMed
236350985Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy.Sci Transl Med2022https://conductscience.org/library/papers/36350985PubMed
335764740The status of tumor mutational burden and immunotherapy.Nat Cancer2022https://conductscience.org/library/papers/35764740PubMed
430541742Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.Cancer Res2019https://conductscience.org/library/papers/30541742PubMed
535952319Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.JCO Precis Oncol2022https://conductscience.org/library/papers/35952319PubMed
631488153Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.J Transl Med2019https://conductscience.org/library/papers/31488153PubMed
729330207Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.Clin Cancer Res2018https://conductscience.org/library/papers/29330207PubMed
831518912Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.Lung Cancer2019https://conductscience.org/library/papers/31518912PubMed
930013197Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.Nat Med2018https://conductscience.org/library/papers/30013197PubMed
1030393817Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.Acta Derm Venereol2019https://conductscience.org/library/papers/30393817PubMed
1135121950Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.Nat Cancer2020https://conductscience.org/library/papers/35121950PubMed
1227718847Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.N Engl J Med2016https://conductscience.org/library/papers/27718847PubMed
1329658856Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.N Engl J Med2018https://conductscience.org/library/papers/29658856PubMed
1436534496Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.Clin Cancer Res2023https://conductscience.org/library/papers/36534496PubMed
1534158359Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.Clin Cancer Res2021https://conductscience.org/library/papers/34158359PubMed
1630573519Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.Cancer Res2019https://conductscience.org/library/papers/30573519PubMed
1733323406The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.Clin Cancer Res2021https://conductscience.org/library/papers/33323406PubMed
1832816849Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.Cancer Discov2020https://conductscience.org/library/papers/32816849PubMed
1930093454Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.Clin Cancer Res2018https://conductscience.org/library/papers/30093454PubMed
2035688557Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy.J Immunother Cancer2022https://conductscience.org/library/papers/35688557PubMed

See all 28 referencesDownload CSV of references

Cited by127

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 152 citations.

PMIDTitleJournalYearIn PapersSource
42953478Cellular origins and evolutionary dynamics of plasma cfDNA in solid tumors: integrating germline, tumor-derived, and hematopoietic variation for MRD and treatment guidance.Front Cell Dev Biol2026https://conductscience.org/library/papers/42953478PubMed
42882934The Dynamic Role of Liquid Biopsy in Patients with Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: Emerging Opportunities and Clinical Challenges.Cancers (Basel)2026https://conductscience.org/library/papers/42882934PubMed
42882836Refining Lung Cancer Care: The Emerging Role of Liquid Biopsy in Screening, Diagnosis, and Precision Oncology.Cancers (Basel)2026https://conductscience.org/library/papers/42882836PubMed
42871719Concordance of tumor-informed and tumor-agnostic ctDNA assays for treatment response monitoring in advanced solid tumors.J Liq Biopsy2026https://conductscience.org/library/papers/42871719PubMed
42854587Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial.ESMO Open2026https://conductscience.org/library/papers/42854587PubMed
42824111Circulating tumor DNA molecular response as a complementary biomarker to RECIST in immune checkpoint inhibitor therapy: current evidence and future directions.Front Oncol2026https://conductscience.org/library/papers/42824111PubMed
42821157Mechanisms of systemic immune modulation in tumor development: Interactions across lymph nodes, bone marrow, and blood.Cancer Metastasis Rev2026https://conductscience.org/library/papers/42821157PubMed
42807637Immune-related biomarkers in liquid biopsy for cancer: emerging tools for non-invasive precision oncology.Front Cell Dev Biol2026https://conductscience.org/library/papers/42807637PubMed
42803873Applications of circulating tumor DNA in unresectable and advanced non-small cell lung cancer immunotherapy: from stratification to therapeutic guidance.Clin Transl Oncol2026https://conductscience.org/library/papers/42803873PubMed
42800800MammaTrace - a tumor naïve cell-free DNA methylation test for minimal residual disease in breast cancer.NPJ Precis Oncol2026https://conductscience.org/library/papers/42800800PubMed
42763389Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design.Mol Cancer2026https://conductscience.org/library/papers/42763389PubMed
42694453Circulating tumor DNA in lung cancer immunotherapy: prognostic marker today, predictive tool tomorrow?Front Immunol2026https://conductscience.org/library/papers/42694453PubMed
42639369Liquid biopsies for detection, characterization, and interception of therapy resistance in thoracic malignancies.Front Oncol2026https://conductscience.org/library/papers/42639369PubMed
42569325Early tumor-informed circulating tumor DNA (ctDNA) dynamics correlate with response to first-line advanced NSCLC treated with pembrolizumab ± chemotherapy.J Liq Biopsy2026https://conductscience.org/library/papers/42569325PubMed
42568819Biomarkers for predicting and monitoring the efficacy of cancer vaccines.Front Oncol2026https://conductscience.org/library/papers/42568819PubMed
42557506Immune response to DNA and RNA: structural insights, molecular mechanisms, and therapeutic targeting.Mol Biomed2026https://conductscience.org/library/papers/42557506PubMed
42539880Targeting tumor transition windows.Explor Target Antitumor Ther2026https://conductscience.org/library/papers/42539880PubMed
42498740Towards liquid biopsy-based analysis of antitumour immunity.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/42498740PubMed
42477682CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions.Cancer Cell Int2026https://conductscience.org/library/papers/42477682PubMed
42416486Predictive value of baseline levels and early dynamic changes of ctDNA for 28-day mortality in ICU patients with advanced lung cancer: a prospective single-center cohort study.Front Mol Biosci2026https://conductscience.org/library/papers/42416486PubMed

See all 127 cited byDownload CSV of cited by

Genes13

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
PEMBROLIZUMABCHEMBL3137343Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3137343

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37814061

GET https://conductscience.org/api/papers/v1/37814061/references?page=2